119-41-5

Basic information

• Product Name: efloxate
• Synonyms: efloxate;EFLOXATE/EFLOXATEM;Corosamin;Domucor;Eflocor;Oxyflavyl;Recordil;2-(4-keto-2-phenyl-chromen-7-yl)oxyacetic acid ethyl ester
• CAS NO: 119-41-5
• Molecular Formula: C₁₉H₁₆O₅
• Molecular Weight: 324.35
• EINECS: 204-321-9
• Mol File: 119-41-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 123-124°
• Boiling Point: 382.67°C (rough estimate)
• Flash Point: 269.1°C
• Appearance: /
• Density: 1.1919 (rough estimate)
• Vapor Pressure: 1.28E-09mmHg at 25°C
• Refractive Index: 1.6120 (estimate)
• CAS DataBase Reference: efloxate(CAS DataBase Reference)
• NIST Chemistry Reference: efloxate(119-41-5)
• EPA Substance Registry System: efloxate(119-41-5)

Safety Data

• Hazardous Substances Data: 119-41-5(Hazardous Substances Data)

Usage

General Description

Eloxate is a chemical compound that belongs to the family of fluoroquinolone antibiotics. It is primarily used for the treatment of bacterial infections such as urinary tract infections, respiratory tract infections, and skin infections. Eloxate works by inhibiting the enzymes that are essential for the replication and repair of bacterial DNA, thereby stopping the growth and proliferation of the bacteria. It is administered orally or intravenously and is typically well-tolerated with few reported side effects. However, it is important to use Eloxate only as directed by a healthcare professional and to be aware of potential drug interactions and allergic reactions.

InChI:InChI=1/C19H16O5/c1-2-22-19(21)12-23-14-8-9-15-16(20)11-17(24-18(15)10-14)13-6-4-3-5-7-13/h3-11H,2,12H2,1H3

Upstream product

• 7436-90-0 2,2-dibromostyrene 
• 96089-43-9 2-hydroxy-4-<(carboxymethyl)oxy>benzaldehyde ethyl ester 
• 5465-06-5 <4-(benzoyloxy)-2-hydroxybenzoyl>benzoylmethane 
• 98-88-4 benzoyl chloride 
• 38256-07-4 1-(2',4'-dihydroxyphenyl)-3-phenyl-propane-1,3-dione 
• 102019-14-7 (4-acetyl-3-benzoyloxy-phenoxy)-acetic acid ethyl ester 
• 2430-55-9 7-ethoxy-carbonylmethoxyflavanone 
• 40433-33-8 (4-acetyl-3-hydroxyphenoxy)acetic acid ethyl ester 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 6665-86-7 7-hydroxyflavone 
• 105-39-5 chloroacetic acid ethyl ester 
• 21591-05-9 [3-hydroxy-4-(3-oxo-3-phenyl-propionyl)-phenoxy]-acetic acid ethyl ester 
• 97980-65-9 2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetic acid 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 97980-65-9 2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetic acid 
• 301206-12-2 N-(6-amino-3-methyl-2,4-dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-(4-oxo-2-phenyl-4H-chromen-7-yloxy)-acetamide 

Relevant articles and documents

Synthesis and anti-inflammatory in vitro, in silico, and in vivo studies of flavone analogues

Chrysin and 7-hydroxy flavone were prepared by Baker-Venkatraman rearrangement followed by esterification at 7th position and replacement of ester with acetamide linking to different heterocyclic moieties synthesized 13a-g and 14a-g series of flavones analogues. These were screened against COX-2 and COX-1 enzymes for inhibition by in vitro assay and COX-2 for in silico docking studies. The compound 14a was found to be most active with IC50 of 3.11 μM concentration, with highest binding energy of -12.4 kcal/mole and 77.2 and 80.5 % inhibition at 3 and 5 h post-carrageenan induced in paw oedema.

Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells

In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I.

Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction

In order to find novel nonsteroidal compounds possessing an inhibitory activity against delayed-type hypersensitivity (DTH) reactions, we conducted random screening using a picryl chloride (PC)-induced contact hypersensitivity reaction (CHR) in mice, and found compound 1 as a lead compound. Then we synthesized and evaluated an extensive series of 5-carboxamidouracil derivatives focused on both the uracil and the antioxidative moieties. Among them, we found that the hindered phenol moiety was necessary to exhibit the activities; especially, compounds 28a-28c having the partial structure of vitamin E were found to exert potent activities against the DTH reaction by both oral and topical administration. And compound 28c showed antioxidative activity against lipid peroxidation with an IC50 of 5.9μM. Compound 28c (CX-659S) was chosen as a candidate drug for the treatment of cutaneous disorders such as atopic dermatitis and allergic contact dermatitis. Copyright (C) 2000 Elsevier Science Ltd.